kabutan

Kyowa Kirin Co., Ltd.(4151) Summary

4151
TSE Prime
Kyowa Kirin Co., Ltd.
2,543.0
JPY
-26.0
(-1.01%)
Dec 5, 3:30 pm JST
16.45
USD
Dec 5, 1:30 am EST
Result
PTS
outside of trading hours
2,541.4
Dec 5, 3:24 pm JST
Summary Chart Historical News Financial Result
PER
23.3
PBR
1.57
Yield
2.36%
Margin Trading Ratio
33.62
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
2,554.5 JPY 16.46 USD
Previous Close Dec 4
2,569.0 JPY 16.53 USD
High Dec 5, 9:01 am
2,559.0 JPY 16.50 USD
Low Dec 5, 12:30 pm
2,509.0 JPY 16.18 USD
Volume
751,400
Trading Value
1.91B JPY 0.01B USD
VWAP
2538.17 JPY 16.42 USD
Minimum Trading Value
254,300 JPY 1,645 USD
Market Cap
1.34T JPY 8.68B USD
Number of Trades
2,225
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
2,797
1-Year High May 2, 2025
11,280
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 49,700 197,400 3.97
Nov 21, 2025 89,900 210,600 2.34
Nov 14, 2025 38,600 139,000 3.60
Nov 7, 2025 31,800 177,500 5.58
Oct 31, 2025 76,800 211,000 2.75
Company Profile
Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Group, focusing on pharmaceutical business and new drug development through its biotechnology division. The company has formed a partnership with Fujifilm.
Sector
Pharmaceuticals
Kyowa Kirin Co., Ltd. primarily engages in the manufacture and sale of prescription pharmaceuticals. The company has numerous subsidiaries and equity-method affiliates, with Kirin Holdings as its parent company. Kyowa Kirin operates globally, with a particular focus on four key markets: Japan, North America, Europe, and Asia-Oceania. The company excels in biopharmaceutical development, possessing a unique drug discovery platform centered on antibody drug development and manufacturing technologies. Kyowa Kirin concentrates on creating new drugs that address unmet medical needs, particularly in disease areas such as nephrology, oncology, and immunology-allergy.